Impact of EBV infection and immune function assay for lymphoproliferative disorder in pediatric patients after liver transplantation: A single-center experience

Tian Qin, Xiang Qian Gu, Seog Song Jeong, Yan Yan Song, Jin Chuan Liu, Jian Xin Zheng, Feng Xue*, Qiang Xia

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)


Background: Post-transplant lymphoproliferative disorder (PTLD) is a lethal complication after pediatric liver transplantation, but information regarding risk factors for the development of PTLD remains unclear. This study was to identify characteristics and risk factors of PTLD. Methods: A total of 705 pediatric patients who underwent liver transplantation between January 2017 and October 2018 were studied. Impact of clinical characteristics and Epstein-Barr virus (EBV) infection on the development of PTLD was evaluated. In addition, ImmuKnow assay was adopted in partial patients to analyze the immune status. Results: Twenty-five (3.5%) patients suffered from PLTD with a median time of 6 months (3–14 months) after transplantation. Extremely high tacrolimus (TAC) level was found in 2 fatal cases at PTLD onset. EBV infection was found in 468 (66.4%) patients. A higher peak EBV DNA loads (>9590 copies/mL) within 3 months was a significant indicator for the onset of PTLD. In addition, the ImmuKnow assay demonstrated that overall immune response was significantly lower in patients with EBV infection and PTLD (P
Original languageEnglish
Pages (from-to)3-11
Number of pages9
JournalHepatobiliary and Pancreatic Diseases International
Issue number1
Publication statusPublished - 1-Feb-2020
Externally publishedYes


  • Epstein-Barr virus
  • Pediatric liver transplantation
  • Post-transplant lymphoproliferative disorder

Cite this